Exclusive Summary

• **Advanced Development Stage**: The 'Clinical in C' status (Clinical trials in China) provides tangible clinical data, accelerating registration in emerging markets that accept foreign data, offering a clear edge over competitors only at the CMC stage.
• **Flexible Licensing Model**: Offering the asset via Licensing allows partners to leverage existing clinical results, significantly lowering their R&D risks and upfront investment while shortening the time-to-market.
• **Supply Chain Cost Advantage**: Leveraging China's integrated manufacturing capabilities ensures a competitive cost structure compared to originators, guaranteeing attractive margins for global partners.

Asset Materials

Contact Us for Full Materials